IGC Pharma has included Hamilton Health Sciences in Canada as a new clinical site for its Phase II CALMA trial of IGC-AD1 to treat Alzheimer's-related agitation. This move aims to advance the therapy towards commercialization by evaluating its efficacy and gathering pharmacokinetic data and biomarkers.